Comparison
While AOD-9604 is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials71111115, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While AOD-9604 works as a synthetic fragment of human growth hormone corresponding to residues 176–191 with an added N-terminal tyrosine, retaining lipolytic but not growth-promoting actions; proposed to stimulate lipolysis and inhibit lipogenesis in adipose tissue, partly via β3-adrenergic pathways without significantly activating the full GH receptor–IGF-1 axis6171111, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
AOD-9604 is 16 amino acids long, whereas Liraglutide is longer as it has a length of 31 amino acids. AOD-9604 is made up of a sequence of Tyrosine, Leucine, Arginine, Isoleucine, Valine, Glutamine, Cysteine, Arginine, Serine, Valine, Glutamic acid, Glycine, Serine, Cysteine, Glycine, Phenylalanine. Liraglutide is made up of a sequence of sequence data not available in the current dataset.
AOD-9604
GH1
Liraglutide
GCG